|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Acute fatty liver of pregnancy associated with severe acute pancreatitis:A case report显示文摘Acute fatty liver of pregnancy is a rare disease that affects women in the third trimester of pregnancy. Although infrequent, the disease can cause maternal mortality. The diagnosis is not always clear until the pregnancy is terminated, and significant complications, such as acute pancreatitis, can occur. Pancreatic involvement typically only occurs in severe cases after the development of hepatic and renal impairment. To date, little knowledge is available regarding how the disease causes pancreatitis. Treatment involves supportive measures and pregnancy interruption. In this report, we describe a case of a previously healthy 26-year-old woman at a gestational age of 27 wk and 6 d who was admitted with severe abdominal pain and vomiting. This case illustrates the clinical and laboratory overlap between acute fatty liver of pregnancy and pancreatitis, highlighting the difficulties in differentiating each disease. Furthermore, the hypothesis for this overlapping is presented, and the therapeutic options are discussed. | Cássio Vieira de Oliveira Alecsro Moreira Julio P Baima Leticia de C Franzoni Talles B Lima Fabio da S Yamashiro Kunie Yabuki Rabelo Coelho Ligia Y Sassaki Carlos Antonio Caramori Ferno G Romeiro Giovanni F Silva | 2014 | World Journal of Hepatology2014，6，7： | 3 |
| 2 | Demodicidosis revisited显示文摘 | Baima B Sticherling M | 2002 | Acta Derm Venereol2002，82，1： | 1 |
| 3 | Demodicidosis revisited显示文摘 | Baima B Sticherling M | 2002 | Acta Derm Ven-ereol2002，82，1： | 1 |
| 4 | Demodicidosis revisited 显示文摘 | Baima B Sticherling M | 2002 | Acta DermVenereol2002，82，1： | 1 |
| 5 | Demodicidosis revisited 显示文摘 | B Baima M Sticherling | 2002 | Acta DennVenereo12002，82，： | 1 |
| 6 | Apoptosis in different cutaneousmanifestations of lupus erythematosus显示文摘 | Baima B Sticherling M | 2001 | Br J Derma-tol2001，144，15： | 1 |
| 7 | Bullous pemphigoid manifesting as dyshidrotic eczema and prurigo nodularis 显示文摘 | Baima B Sticherling M | 2002 | Hautarzt2002，53，11： | 1 |
| 8 | Demodicidosis revisited显示文摘 | Baima B Sticherling M | 2002 | Acta Derm Venereol2002，82，1： | 1 |
| 9 | Demodicidosis revisited显示文摘 | Baima B Sticherling M | | 0，，01： | 1 |
| 10 | Demodicidosis revisited显示文摘 | Baima B Sticherling M | 2002 | Acta Derm Venereol2002，82，： | 1 |
| 11 | Apoptosis in different cutaneous manifestations of lupus erythematosus显示文摘 | Baima B Sticherling M | 2001 | Br J Dematol2001，144，5： | 1 |
| 12 | Demodicidosis revisited显示文摘 | Baima B Sticherling M | 2002 | Acta Derm Venereol2002，82，1： | 1 |
| 13 | Demodicidosis revisited显示文摘 | Baima B Sticherling M | 2002 | Acta Derm Vcnercol2002，82，1： | 1 |
| 14 | Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil显示文摘BACKGROUND Crohn’s disease(CD)and ulcerative colitis(UC)are inflammatory bowel diseases(IBDs)with a remission-relapsing presentation and symptomatic exacerbations that have detrimental impacts on patient quality of life and are associated with a high cost burden,especially in patients with moderate-to-severe disease.The Real-world Data of Moderate-to-Severe Inflammatory Bowel Disease in Brazil(RISE BR)study was a noninterventional study designed to evaluate disease control,treatment patterns,disease burden and health-related quality of life in patients with moderate-to-severe active IBD.We report findings from the prospective follow-up phase of the RISE BR study in patients with active UC or CD.AIM To describe the 12-mo disease evolution and treatment patterns among patients with active moderate-to-severe IBD in Brazil.METHODS This was a prospective,noninterventional study of adult patients with active Crohn’s disease(CD:Harvey-Bradshaw Index≥8,CD Activity Index≥220),inadequate CD control(i.e.,calprotectin>200μg/g or colonoscopy previous results),or active ulcerative colitis(UC:Partial Mayo score≥5).Enrollment occurred in 14 centers from October 2016 to February 2017.The proportion of active IBD patients after 9-12 mo of follow-up,Kaplan-Meier estimates of the time to mild or no activity and a summary of treatment initiation,discontinuation and dose changes were examined.RESULTS The study included 118 CD and 36 UC patients,with mean±SD ages of 43.3±12.6 and 44.9±16.5 years,respectively.The most frequent drug classes at index were biologics for CD(62.7%)and 5-aminosalicylate derivates for UC patients(91.7%).During follow-up,65.3%of CD and 86.1%of UC patients initiated a new treatment at least once.Discontinuations/dose changes occurred in 68.1%of CD patients[median 2.0(IQR:2-5)]and 94.3%of UC patients[median 4.0(IQR:3-7)].On average,CD and UC patients had 4.4±2.6 and 5.0±3.3 outpatient visits,respectively.The median time to first mild or no activity was 319(IQR:239-358)d for CD and 320(IQR:288-358)d for UC patients.At 9-12 mo,22.0%of CD and 20.0%of UC patients had active disease.CONCLUSION Although a marked proportion of active IBD patients achieved disease control within one year,the considerable time to achieve this outcome represents an unmet medical need of the current standard of care in a Brazilian real-world setting. | Ligia Yukie Sassaki Sender J Miszputen Roberto Luiz Kaiser Junior Wilson R Catapani Mauro Bafutto António S Scotton Cyrla Zaltman Julio Pinheiro Baima Hagata S Ramos Mikaell Alexandre Gouvea Faria Carolina D Gonçalves Isabella Miranda Guimaraes Cristina Flores Heda M B S Amarante Rodrigo Bremer Nones JoséMiguel Luz Parente Murilo Moura Lima Júlio Maria Chebli Maria de Lourdes Abreu Ferrari Julia F Campos Maria G P Sanna Odery Ramos Rogério Serafim Parra Jose J R da Rocha Omar Feres Marley R Feitosa Rosana Fusaro Caratin Juliana Tosta Senra Genoile Oliveira Santana | 2021 | World Journal of Gastroenterology2021，27，23： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员